Duncan Smith (Dublin Fingal, Labour)
Link to this: Individually | In context | Oireachtas source

225. To ask the Minister for Health if a person (details supplied) in County Kildare can avail now of a vaccine; and if he will make a statement on the matter. [56278/21]

Stephen Donnelly (Wicklow, Fianna Fail)
Link to this: Individually | In context | Oireachtas source

The immunisation programme in Ireland is based on the advice of the National Immunisation Advisory Committee (NIAC). The committee's recommendations are based on the prevalence of the relevant disease in Ireland and international best practice in relation to immunisation. It makes recommendations on vaccination policy to my Department. The NIAC continues to revise recommendations to allow for the introduction of new vaccines in Ireland and to keep abreast of changes in the patterns of disease. Therefore, the immunisation schedule will continue to be amended over time.

In 2009, the NIAC recommended HPV (human papillomavirus) vaccination for all 12 to 13 year old girls to reduce their risk of developing cervical cancer when they are adults. In September 2010, the HPV vaccination programme was introduced for all girls in first year of secondary school.

In June 2017, on foot of the NIAC’s recommendation that the HPV vaccine should also be given to boys, my Department asked the Health Information and Quality Authority (HIQA) to undertake a health technology assessment (HTA) to establish the clinical and cost-effectiveness of extending the immunisation programme to include boys in the first year of secondary school.

The HIQA completed the HTA in December 2018, recommending that the HPV immunisation programme be extended to include boys. A policy decision was made to extend the HPV immunisation programme to include boys, starting in September 2019, with the introduction of a 9-valent HPV vaccine.

The ages at which vaccines are recommended in the immunisation schedule are chosen by the NIAC in order to give each child the best possible protection against vaccine preventable diseases. As the HPV vaccine is preventative it is intended to be administered, if possible, before a person becomes sexually active, that is, before a person is first exposed to HPV infection.

Therefore, the gender-neutral HPV vaccination programme targets all girls and boys in first year of secondary school to provide maximum coverage. All vaccines administered through the School Immunisation Programme are provided free of charge.

My Department will continue to be guided by NIAC's recommendations on any emerging evidence on this issue in the future.

Anyone not in 1st year of secondary school or age equivalent in special schools or home schooled during the 2020/2021 school year who wishes to get the HPV vaccine, must go to their GP or sexual health clinic and pay privately for the vaccine and its administration. This applies to everyone whether or not they have a medical card/GP visit card, as it is outside of the HPV immunisation programme.

My Department has asked the National Immunisation Advisory Committee to consider the clinical effectiveness of providing the HPV vaccine to:

- girls and boys in secondary school who were eligible to receive HPV vaccine in 1st year but who did not receive it; and

- women up to the age of 25 years who have left secondary school and who did not receive the vaccine when eligible.

If NIAC conclude that there is sufficient evidence to support providing the HPV vaccine to one or both groups, HIQA will undertake a cost-effectiveness assessment on that basis.

James O'Connor (Cork East, Fianna Fail)
Link to this: Individually | In context | Oireachtas source

226. To ask the Minister for Health the position regarding booster vaccines for persons under 60 years of age that have serious underlying health conditions; and if he will make a statement on the matter. [56283/21]

Stephen Donnelly (Wicklow, Fianna Fail)
Link to this: Individually | In context | Oireachtas source

The immunisation programme in Ireland is based on the advice of the National Immunisation Advisory Committee (NIAC). The NIAC makes recommendations on vaccination policy to my Department based on the prevalence of the relevant disease in Ireland and international best practices in relation to immunisation.

On 15 November the NIAC recommended that a booster of an mRNA vaccine be offered to persons aged 16-59 years with underlying conditions, all residents in Long Term Healthcare Facilities and persons aged 50-59 years. The Chief Medical Officer has endorsed the latest NIAC recommendations and written to the HSE to request that the recommendations be operationalised as soon as possible.

The NIAC has previously recommended that a booster dose of an mRNA vaccine (irrespective of whether the primary vaccination course was of an mRNA or adenoviral vector) be offered to those aged 60 years and older and healthcare workers. The booster dose should be given after an interval of six months (or at least five months) following the last dose of any authorised Covid-19 vaccine. I have accepted this advice and the HSE has made the necessary arrangements to operationalise these recommendations with the booster rollout now underway.

The NIAC has also recommended an additional mRNA dose should be given to those aged 12 years and older with immunocompromise associated with a suboptimal response to vaccination who have completed their primary vaccination course. The third dose of an mRNA vaccine should be given a minimum of two months after the last dose of the primary vaccination schedule.

The NIAC will continue to examine emerging evidence regarding booster vaccines for others in the population where there is evidence of waning immunity and reduced effectiveness and will make further recommendations if required.